DGAP-News: SYNLAB delivers outstanding financial and operational results in Q2 and H1 2021
Excluding SARS-CoV-2 testing, but including the tailwind from lower attrition, total organic growth was +25% in H1 2021 and +44% in Q2 2021 alone.
- Excluding SARS-CoV-2 testing, but including the tailwind from lower attrition, total organic growth was +25% in H1 2021 and +44% in Q2 2021 alone.
- - Germany (19%) recorded underlying organic growth of 2.9% in H1 2021, driven by strong Q2 2021 volumes and a catch-up effect following slower growth in Q1 2021.
- H1 2021 adjusted EBITDA increased by 3.4x and reached EUR 663 million (H1 2020: EUR 193 million).
- Total CAPEX (including Leases and related interest payments) was EUR 95 million in H1 2021 (EUR 84 million in H1 2020) representing 4.9% of H1 2021 revenue (8.5% in H1 2020).